We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+10.97%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.05B
AUM Growth
+$206M
Cap. Flow
-$221M
Cap. Flow %
-4.38%
Top 10 Hldgs %
83.23%
Holding
98
New
29
Increased
15
Reduced
26
Closed
6

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$8.14M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$7.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$6.05M
4
ATRA icon
Atara Biotherapeutics
ATRA
+$4.89M
5
NTB icon
Bank of N.T. Butterfield & Son
NTB
+$4.86M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$699M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.1M
3
C icon
Citigroup
C
+$10.6M
4
BABA icon
Alibaba
BABA
+$9.27M
5
APTV icon
Aptiv
APTV
+$8.43M

Sector Composition

Rank Sector Weight
1 Consumer Staples 41.33%
2 Healthcare 27.87%
3 Consumer Discretionary 7.22%
4 Financials 1.42%
5 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.08B 41.15%
87,460,875
-27,526,672
-24% -$699M
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$1.04B 20.58%
57,517,977
– –
GS icon
3
CALL
Goldman Sachs
GS
$289B
$443M 8.78%
2,750,000
+1,500,000
+120% +$244M
WW
4
DELISTED
WW International
WW
$304M 6.02%
29,443,300
– –
BAC icon
5
CALL
Bank of America
BAC
$429B
$78.3M 1.55%
5,000,000
– –
CELG
6
CALL
DELISTED
Celgene Corp
CELG
$73.2M 1.45%
700,000
+500,000
+250% +$54.1M
INCY icon
7
Incyte
INCY
$25.4B
$56.6M 1.12%
600,000
-25,000
-4% -$2.11M
BIIB icon
8
CALL
Biogen
BIIB
$30.9B
$47M 0.93%
150,000
– –
BMY icon
9
CALL
Bristol-Myers Squibb
BMY
$129B
$43.1M 0.85%
+800,000
New +$51.4M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$38.3B
$40.7M 0.81%
600,000
-110,000
-15% -$7.76M
REGN icon
11
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
$40.2M 0.8%
100,000
-20,000
-17% -$8.02M
FXI icon
12
CALL
iShares China Large-Cap ETF
FXI
$4.32B
$38M 0.75%
+1,000,000
New +$36.7M
WMT icon
13
CALL
Walmart Inc
WMT
$909B
$36.1M 0.71%
1,500,000
– –
MET icon
14
CALL
MetLife
MET
$62.4B
$33.3M 0.66%
841,500
+280,500
+50% +$10.5M
GS icon
15
Goldman Sachs
GS
$289B
$32.3M 0.64%
200,000
– –
GOOGL icon
16
CALL
Alphabet (Google) Class A
GOOGL
$4.12T
$32.2M 0.64%
800,000
– –
CMG icon
17
CALL
Chipotle Mexican Grill
CMG
$43.9B
$31.8M 0.63%
+3,750,000
New +$30.8M
BABA icon
18
Alibaba
BABA
$276B
$31.7M 0.63%
300,000
-100,000
-25% -$9.27M
ALXN
19
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$30.6M 0.61%
+250,000
New +$32.2M
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$11.9B
$27.8M 0.55%
300,000
-50,000
-14% -$4.71M
AGIO icon
21
CALL
Agios Pharmaceuticals
AGIO
$2.08B
$26.4M 0.52%
+500,000
New +$21.8M
BLUE
22
DELISTED
bluebird bio
BLUE
$26.1M 0.52%
29,722
-5,018
-14% -$3.63M
ARRY
23
DELISTED
Array Biopharma Inc
ARRY
$23.6M 0.47%
3,500,000
-370,000
-10% -$1.43M
AGIO icon
24
Agios Pharmaceuticals
AGIO
$2.08B
$21.1M 0.42%
400,000
+25,000
+7% +$1.09M
KITE
25
DELISTED
Kite Pharma, Inc.
KITE
$17.6M 0.35%
315,000
-10,000
-3% -$557K
1
2 3 4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2016 Portfolio in Review

As of Q3 2016, Artal Group held 98 positions worth $5.05B, up 4.3% from $4.84B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $221M in Q3 2016, closing 6 positions and reducing 26 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $20.1M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 41% of assets, down from 56% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Sage Therapeutics worth $9.21M.

  • Artal Group's largest Q3 2016 buy was Sage Therapeutics: 200,000 shares worth $9.21M.
  • Artal Group added most to Amicus Therapeutics in Q3 2016, an estimated $4.39M increase.
  • Artal Group's biggest Q3 2016 reduction was Blue Buffalo Pet Products, Inc, cutting an estimated $699M.
  • Artal Group fully exited Regeneron Pharmaceuticals in Q3 2016, selling an estimated $20.1M.
  • Artal Group's ten largest holdings make up 83% of its $5.05B portfolio in Q3 2016.
  • Artal Group opened 29 new positions and closed 6 in Q3 2016.
  • Artal Group's portfolio value rose 4.3% quarter-over-quarter to $5.05B.

Based on Artal Group's 13F filing for Q3 2016, filed 14 Nov 2016.